Clinical Trial: Assessment of the Potential Interactions between Cocaine and GBR 12909


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Assessment of the Potential Interactions between Cocaine and GBR 12909 - 1

This study is currently recruiting patients.

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this study is to assess the potential interactions between iv cocaine and GBR 12909.

Condition	Treatment or Intervention	Phase
Cocaine-Related Disorders	Drug: GBR 12909	Phase I

MedlinePlus related topics: Cocaine Abuse

Study Type: Interventional
Study Design: Treatment, Double-Blind, Dose Comparison

Official Title: Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study with Three Dosages of GBR 12909 in Cocaine Experienced Volunteers

Further Study Details:

Expected Total Enrollment: 24

Study start: August 2002; Study completion: September 2003

This is a single dose with escalation, double-blind, placebo-controlled inpatient study in which 24 cocaine experienced volulnteers that meet protocol eligibility criteria during a 30 day screen period will be randomized into three dose groups.

Eligibility

Ages Eligible for Study: 18 Years - 45 Years, Genders Eligible for Study: Both

Criteria

Inclusion Criteria:

Must understand study procedures and provide written informed consent
For additional inclusion criteria information, please contact study site for more information.

Exclusion Criteria:

Please contact study site for more information.

Location and Contact Information

Louis Cantilena, M.D. (301)295-3240

Maryland
Uniformed Services University of Health Science, Bethesda, Maryland, 20814 4799, United States; Recruiting

Louis Cantilena, M.D. 301-295-3240

Study chairs or principal investigators

Louis Cantilena, M.D., Principal Investigator, Uniformed Services University of Health Science

More Information

Study ID Numbers: NIDA-CPU-GBR12909-01-1
Record last reviewed: September 2004
Record first received: January 17, 2003
ClinicalTrials.gov Identifier: NCT00051896
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-08

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services